PBYI stock forecast, quote, news & analysis
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients... Show more
Why Puma Biotechnology (PBYI) Is Up +16% in the Last 30 Days
Key Takeaways
- PBYI stock rose approximately +16% over the last 30 days, recovering from post-earnings lows amid technical breakout above the 200-day moving average.
- Over the past quarter, shares gained +14%, reflecting sustained momentum from strong full-year 2025 profitability and pipeline progress.
- Key drivers include robust NERLYNX demand, positive clinical developments for alisertib, and overall biotech sector sentiment.
- Q4 2025 earnings beat estimates but initial weakness from 2026 guidance; recovery highlights investor focus on fundamentals.
- Trading above 50-day ($6.52) and 200-day ($5.26) moving averages signals bullish trend in stock price analysis.
Puma Biotechnology (PBYI) Company Overview and Market Position
Puma Biotechnology, Inc. (PBYI) is a biopharmaceutical company focused on the development and commercialization of innovative products to enhance cancer care. Its core product, NERLYNX (neratinib), is an oral prescription medicine used to treat early-stage and metastatic HER2-positive breast cancer. The company in-licenses drug candidates that have completed initial clinical testing, advances them through development, and commercializes them primarily in the U.S. via third-party manufacturers and distributors.
In the competitive oncology sector, Puma holds a niche position with NERLYNX generating the majority of revenue, supplemented by royalty income. Strong fundamentals, including three consecutive years of profitability and a solid cash position of nearly $100 million, underpin recent stock price resilience despite biotech volatility. This exposure to HER2-targeted therapies explains recovery in price movement as demand stabilizes and pipeline catalysts emerge.
Puma Biotechnology (PBYI) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PBYI stock climbed +16%, trading from around $5.90-$6.20 to approximately $6.90-$7.00. The movement was volatile initially, dipping post-Q4 earnings in late February before steadily recovering with a trend-driven upswing, breaking above key moving averages.
For the past quarter, shares advanced +14%, from roughly $6.20 to current levels. Performance featured an early post-earnings pullback followed by range-bound consolidation and a bullish breakout, reflecting improved market trends in small-cap biotech. Volume averaged 400,000 shares daily, supporting the upward trajectory.
What Drove PBYI Stock Price in the Last 30 Days
PBYI's 30-day rally stemmed from technical factors and renewed confidence in operations. Shares crossed above the 200-day moving average around mid-March, a classic bullish signal in stock analysis that attracted momentum traders. This followed a sharp post-earnings drop in late February, where Q4 2025 results beat estimates—adjusted EPS of $0.29 versus $0.24 expected, revenues up 15% to $75.5 million—but weak 2026 guidance ($214-$221 million total revenue) triggered selling.
Recovery gained traction as investors digested sustained NERLYNX sales ($55 million in Q4) and alisertib trial progress, including upcoming data presentations. Analyst notes remained neutral but highlighted profitability, bolstering sentiment. Broader biotech optimism amid favorable macro conditions, like stable interest rates, aided the sector lift.
What Drove PBYI Stock Performance Over the Last Quarter
The quarterly +14% gain built on full-year 2025 strength: $228 million total revenue, $31 million net income ($0.61 diluted EPS), and debt reduction to $22.5 million. Institutional interest grew, with short interest at 10.71% of float, setting up a squeeze potential.
Q4 beats initially pressured shares due to guidance below consensus, but cumulative factors like 28% quarterly revenue growth year-over-year, positive conference feedback (e.g., TD Cowen), and alisertib advancements in breast and lung cancer trials drove rebound. Macro tailwinds, including biotech index gains and lower rate expectations, amplified competitive positioning versus peers. Investor behavior shifted to value Puma's cash flow positivity amid industry M&A (mergers and acquisitions) waves.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, scanning thousands of tickers across strategies like day trading, swing trading, and long-term investing. These curated bots are selected based on recent performance metrics, win rates, average returns, and relevance to current market trends, helping users identify automated tools suited to their risk tolerance and timeframe. Whether focusing on momentum plays or value opportunities, the page offers transparent stats and backtests. Explore Trending AI Robots to enhance your stock analysis with data-driven automation.
PBYI Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Q1 2026 earnings for NERLYNX sales trajectory and alisertib Phase 2 data readouts in hormone receptor-positive breast cancer and small cell lung cancer. Upcoming conferences may reveal partnership updates. Macro factors like Fed rate decisions and biotech funding environment could sway sentiment. Risks include guidance revisions or trial setbacks; catalysts encompass label expansions or buyouts in oncology. Track volume and moving averages for continued price movement signals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Momentum Indicator for PBYI turns positive, indicating new upward trend
PBYI saw its Momentum Indicator move above the 0 level on March 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PBYI just turned positive on March 23, 2026. Looking at past instances where PBYI's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
PBYI moved above its 50-day moving average on April 01, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PBYI crossed bullishly above the 50-day moving average on April 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PBYI broke above its upper Bollinger Band on April 08, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.037) is normal, around the industry mean (26.162). P/E Ratio (12.754) is within average values for comparable stocks, (45.457). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.767). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (1.726) is also within normal values, averaging (317.372).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PBYI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer
Industry Biotechnology